Andreas Krause1, Jochen Zisowsky2, Daniel S Strasser3, Martine Gehin2, Patricia N Sidharta2, Peter M A Groenen3, Jasper Dingemanse2. 1. Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123, Allschwil, Switzerland. andreas.krause@actelion.com. 2. Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123, Allschwil, Switzerland. 3. Department of Translational Science, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123, Allschwil, Switzerland.
Abstract
BACKGROUND AND OBJECTIVE: The chemoattractant receptor-homologous molecule expressed on T helper-2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 (PGD2), a key mediator in inflammatory disorders. Two selective and potent CRTH2 antagonists currently in clinical development, ACT-453859 and setipiprant, were compared with respect to their (predicted) clinical efficacy. METHODS:Population pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to characterize how plasma concentrations (PK) of ACT-453859, its active metabolite ACT-463036 and setipiprant related to their effect on blocking PGD2-induced internalization of CRTH2 on eosinophils (PD). Simulations were used to identify doses and dosing regimens leading to 90 % of maximum blockade of CRTH2 internalization at trough. RESULTS: A combined concentration of ACT-453859 and its metabolite ACT-463036, with weights proportional to potency (based on an eosinophil shape change assay), enabled good characterization of the PD effect. The modelling and simulation results facilitated decision making by suggesting an ACT-453859 dose of 400 mg once daily (or 100 mg twice daily) for clinically relevant CRTH2 antagonism. CONCLUSION: Pharmacometric quantification demonstrated that CRTH2 internalization is a useful new biomarker to study CRTH2 antagonism. Ninety percent of maximum blockade of CRTH2 internalization at trough is suggested as a quantitative PD target in clinical studies.
RCT Entities:
BACKGROUND AND OBJECTIVE: The chemoattractant receptor-homologous molecule expressed on T helper-2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 (PGD2), a key mediator in inflammatory disorders. Two selective and potent CRTH2 antagonists currently in clinical development, ACT-453859 and setipiprant, were compared with respect to their (predicted) clinical efficacy. METHODS: Population pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to characterize how plasma concentrations (PK) of ACT-453859, its active metabolite ACT-463036 and setipiprant related to their effect on blocking PGD2-induced internalization of CRTH2 on eosinophils (PD). Simulations were used to identify doses and dosing regimens leading to 90 % of maximum blockade of CRTH2 internalization at trough. RESULTS: A combined concentration of ACT-453859 and its metabolite ACT-463036, with weights proportional to potency (based on an eosinophil shape change assay), enabled good characterization of the PD effect. The modelling and simulation results facilitated decision making by suggesting an ACT-453859 dose of 400 mg once daily (or 100 mg twice daily) for clinically relevant CRTH2 antagonism. CONCLUSION: Pharmacometric quantification demonstrated that CRTH2 internalization is a useful new biomarker to study CRTH2 antagonism. Ninety percent of maximum blockade of CRTH2 internalization at trough is suggested as a quantitative PD target in clinical studies.
Authors: Martine Géhin; Daniel S Strasser; Jochen Zisowsky; Hervé Farine; Peter M A Groenen; Jasper Dingemanse; Patricia N Sidharta Journal: J Clin Pharmacol Date: 2015-03-30 Impact factor: 3.126
Authors: Z Diamant; P N Sidharta; D Singh; B J O'Connor; R Zuiker; B R Leaker; M Silkey; J Dingemanse Journal: Clin Exp Allergy Date: 2014-08 Impact factor: 5.018
Authors: R Pettipher; M G Hunter; C M Perkins; L P Collins; T Lewis; M Baillet; J Steiner; J Bell; M A Payton Journal: Allergy Date: 2014-07-14 Impact factor: 13.146
Authors: F G Gervais; R P Cruz; A Chateauneuf; S Gale; N Sawyer; F Nantel; K M Metters; G P O'neill Journal: J Allergy Clin Immunol Date: 2001-12 Impact factor: 10.793
Authors: Anna K Stalder; Dominik Lott; Daniel S Strasser; Hans G Cruz; Andreas Krause; Peter M A Groenen; Jasper Dingemanse Journal: Br J Clin Pharmacol Date: 2016-11-15 Impact factor: 4.335
Authors: Paul Ratner; Charles P Andrews; Frank C Hampel; Bruce Martin; Dale E Mohar; Denis Bourrelly; Parisa Danaietash; Sara Mangialaio; Jasper Dingemanse; Abdel Hmissi; Jay van Bavel Journal: Allergy Asthma Clin Immunol Date: 2017-04-04 Impact factor: 3.406
Authors: Eric D Bateman; Christopher O'Brien; Paul Rugman; Sally Luke; Stefan Ivanov; Mohib Uddin Journal: Drug Des Devel Ther Date: 2018-05-04 Impact factor: 4.162